Acute Myeloid Leukemia: Did You Know?

April 21st, 2021 is Acute Myeloid Leukemia (AML) World Awareness Day. On this day, we want to help raise awareness of this rare, aggressive form of cancer that happens in the blood and bone marrow. It is characterized by an excess of immature white blood cells and low quality red blood cells. It is the […]

Emerging Technical and Precision Medicine Approaches for Higher Risk Myelodysplastic Syndromes

Novel precision medicine approaches such as Notable Labs’ ex vivo DSS identify rational drugs and drug combinations and predict clinical therapeutic responses

Getting the right cancer drugs to the right patients relies on the accurate prediction of clinical response to an ever-increasing array of cancer therapies.

Notable Labs Announces Addition of Thomas Bock to Board of Directors

FOSTER CITY, CA – Oct. 13, 2020 – Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, today announced the addition of Thomas A. Bock to its board of directors.

Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms

Precision medicine approaches such as ex vivo drug sensitivity screening (DSS) are appealing to inform rational drug selection in myelodysplastic syndromes (MDSs) and acute myeloid leukemia, given their marked biologic heterogeneity.

Notable Labs Enters Into Partnership With myTomorrows

FOSTER CITY, CA – Sep. 24, 2020 – Notable, a functional precision medicine company, and myTomorrows, an integrated platform that links patients with an unmet medical need to treatments in development worldwide, are proud to announce their partnership.

September is Blood Cancer Awareness Month

Living with Adult Acute Lymphoblastic Leukemia September is Blood Cancer Awareness Month. The Leukemia & Lymphoma Society® (LLS) is a global leader in the fight against cancer and has helped advance 54 of the 64 blood cancer treatment options approved by the U.S. Food and Drug Administration since 2017. This month the LLS announced it […]

Notable Launches New Clinical Study With Washington University School of Medicine Exploring Ex Vivo Drug Screening to Predict Chemotherapy Sensitivity and Resistance

FOSTER CITY, CA – Aug. 06, 2020 – Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, announced a new precision oncology study with Washington University School of Medicine in St. Louis, exploring the feasibility of ex vivo drug screening to predict sensitivity and resistance to chemotherapy, and to identify novel synergies across a broad panel of anti-cancer therapies.

Emerging Treatment Approaches of High-Risk Myelodysplastic Syndrome

The Stanford University Cancer Center and the MDS Foundation are proud to bring you this complimentary webinar presented by Stanford’s Dr. Michael Spinner, post-doctoral medical fellow, oncology, and moderated by the MDS Foundation’s Sandra Kurtin, Ph.D., ANP-C, AOCN.

How We Capture Mechanism of Action in the Notable Platform

Notable has developed a versatile platform for testing a wide variety of drugs in patient ex vivo clinical samples, with a high-throughput flow cytometry readout that incorporates diverse phenotypes, including measures of apoptosis, proliferation, differentiation, and stemness, as well as immunotherapy targets.

Getting the right cancer drugs to the right patients relies on the accurate prediction of clinical response to an ever-increasing array of cancer therapies.

Notable’s Mission to Move Beyond a “One-Size-Fits-All” Ex Vivo Drug Sensitivity Test

Figure 1: Heatmap showing responses to 31 drugs or drug combinations (rows) in 37 blood cancer patient samples (columns). Each colored box represents the level of ex vivo drug sensitivity, with red indicating the highest level of sensitivity and blue the lowest. Getting the right cancer drugs to the right patients relies on the accurate […]